Novel Poly(L-lactide-co-ε-caprolactone) Matrices Obtained with the Use of Zr[Acac]₄ as Nontoxic Initiator for Long-Term Release of Immunosuppressive Drugs

Table 3

Microstructure of more random PLACL 75:25 matrices containing cyclosporine A or rapamycine (𝐹_LL, 𝐹_Cap: percentage molar content of lactidyl and caproyl unit; 𝑙_LL, 𝑙_Cap: the average length of lactidyl and caproyl sequences; 𝑅: randomization ratio) after 35, 70, 105, and 210 days of degradation.

Matrix	No.	Days	𝐹LL	𝐹Cap	𝑙LL	𝑙Cap	R
More random; PLACL 75 : 25	1	0	75	25	4.28	1.58	0.75
	2	35	74	26	4.02	1.43	0.81
	3	70	74	26	4.00	1.41	0.83
	4	105	78	22	5.72	1.73	0.68
	5	210	82	18	6.67	1.47	0.74
More random; PLACL 75 : 25; + CyA	6	0	75	25	4.28	1.58	0.75
	7	35	73	27	4.03	1.45	0.81
	8	70	73	27	3.66	1.32	0.89
	9	105	75	25	6.23	2.05	0.57
	10	210	81	19	6.37	1.5	0.74
More random; PLACL 75 : 25; + Rap	11	0	75	25	4.28	1.58	0.75
	12	35	73	27	3.99	1.44	0.81
	13	70	73	27	4.39	1.58	0.74
	14	105	75	25	5.28	1.76	0.66
	15	210	82	18	6.68	1.47	0.76